Free Trial
→ This stock has 30 days of quiet left (From Behind the Markets) (Ad)tc pixel Free ARDS Stock Alerts

Aridis Pharmaceuticals (ARDS) Competitors

Aridis Pharmaceuticals logo
$0.0017 0.00 (0.00%)
As of 05/22/2026 03:52 PM Eastern
Compare

ARDS vs. BPTSY, HEPA, BPTH, SRNE, and ONCO

Should you buy Aridis Pharmaceuticals stock or one of its competitors? MarketBeat compares Aridis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aridis Pharmaceuticals include Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Bio-Path (BPTH), Sorrento Therapeutics (SRNE), and Onconetix (ONCO). These companies are all part of the "pharmaceutical products" industry.

How does Aridis Pharmaceuticals compare to Biophytis?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Biophytis shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Biophytis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Biophytis N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.02
BiophytisN/AN/A-$18.43MN/AN/A

Aridis Pharmaceuticals has a beta of 49.37, meaning that its share price is 4,837% more volatile than the broader market. Comparatively, Biophytis has a beta of 2.46, meaning that its share price is 146% more volatile than the broader market.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Biophytis Neutral

Summary

Aridis Pharmaceuticals beats Biophytis on 3 of the 4 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Hepion Pharmaceuticals?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

In the previous week, Hepion Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Hepion Pharmaceuticals Neutral
Aridis Pharmaceuticals Neutral

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.37, suggesting that its share price is 4,837% more volatile than the broader market.

Aridis Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hepion PharmaceuticalsN/A -812.56% -207.31%
Aridis Pharmaceuticals N/A N/A N/A

Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.02

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Hepion Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Bio-Path?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Bio-Path Neutral

Aridis Pharmaceuticals has a beta of 49.37, meaning that its share price is 4,837% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.29, meaning that its share price is 129% less volatile than the broader market.

Aridis Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Bio-Path N/A -2,842.40%-337.48%

Bio-Path is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.02
Bio-PathN/AN/A-$16.08M-$1.06N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aridis Pharmaceuticals beats Bio-Path on 7 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Sorrento Therapeutics?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Aridis Pharmaceuticals has a beta of 49.37, meaning that its share price is 4,837% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.02
Sorrento Therapeutics$60.32M0.00-$572.84M-$0.43N/A

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Sorrento Therapeutics N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Sorrento Therapeutics Neutral

Summary

Aridis Pharmaceuticals beats Sorrento Therapeutics on 6 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Onconetix?

Onconetix (NASDAQ:ONCO) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Aridis Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -1,316.28%. Aridis Pharmaceuticals' return on equity of 0.00% beat Onconetix's return on equity.

Company Net Margins Return on Equity Return on Assets
Onconetix-1,316.28% -101.08% -47.34%
Aridis Pharmaceuticals N/A N/A N/A

Onconetix has a beta of 3.01, meaning that its stock price is 201% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 49.37, meaning that its stock price is 4,837% more volatile than the broader market.

In the previous week, Onconetix had 5 more articles in the media than Aridis Pharmaceuticals. MarketBeat recorded 5 mentions for Onconetix and 0 mentions for Aridis Pharmaceuticals. Aridis Pharmaceuticals' average media sentiment score of 0.00 beat Onconetix's score of -0.40 indicating that Aridis Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Onconetix Neutral
Aridis Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Onconetix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aridis Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Onconetix has higher revenue and earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Onconetix$810K1.75-$14.03M$11.400.11
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.02

23.9% of Onconetix shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 0.3% of Onconetix shares are held by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Onconetix beats Aridis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARDS vs. The Competition

Export
MetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$91K$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio0.021.4621.0025.66
Price / SalesN/A119.63562.1886.31
Price / CashN/A20.0743.4956.67
Price / BookN/A7.5910.417.14
Net Income-$30.37M-$3.64M$3.57B$335.98M
7 Day PerformanceN/A3.01%6.40%4.11%
1 Month PerformanceN/A76.62%3.54%2.52%
1 Year PerformanceN/A126.61%34.14%35.04%

Aridis Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+750.0%$91KN/A0.0230
BPTSY
Biophytis
N/A$0.25
flat		N/AN/A$586KN/AN/A30
HEPA
Hepion Pharmaceuticals
N/A$0.10
+5.7%		N/A+14.9%$491KN/AN/A20
BPTH
Bio-Path
N/A$0.03
-4.0%		N/A-77.2%$282KN/AN/A10
SRNE
Sorrento Therapeutics
N/A$0.00
flat		N/A-61.5%$276K$60.32MN/A800

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel